Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for
patients with relapsed acute myeloid leukemia. In this retrospective, multicenter study, we …

PURPOSE Treatment options for patients with chronic myeloid leukemia (CML) who relapse
after allogeneic bone marrow transplantation (BMT) are limited. Treatment with lymphocytes …

Background The effects of chimerism on outcomes following allogeneic hematopoietic stem
cell transplantation (HSCT) are unclear and may differ between diseases. We retrospectively …

Allogeneic hematopoietic stem cell transplantation is required as rescue therapy in about
20% of pediatric patients with acute lymphoblastic leukemia. However, the relapse rates are …

Serial cytogenetic studies were performed on 64 patients with chronic myelogenous
leukemia (CML) after T cell-depleted allogeneic bone marrow transplantation (BMT). Forty …

Graft-versus-leukemia (GVL) is a major component of the overall beneficial effects of
allogeneic bone marrow transplantation (BMT) in the treatment of leukemia. Although …

Using red cell phenotyping (RCP) and/or cytogenetics (CYT) we identified 19 patients with
persisting mixed chimerism (MC) among 231 patients transplanted with partially T cell …

Allogeneic hematopoietic cell transplantation (HCT) has changed from a treatment modality
often associated with devastating complications to a standard therapy for a variety of …

In patients receiving allogeneic stem cell transplantation (SCT) for treatment of malignant
hematologic disorders, residual leukemia can be assessed by different methodologic …

The association of mixed (donor/host) chimerism with graft-versus-host disease (GVHD),
graft rejection, disease recurrence and survival was investigated in 116 patients with …